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Abstract 
The nature of the product to be discovered guides the reasoning to discover it. Biologists 
and medical researchers often search for mechanisms. The "new mechanistic philosophy 
of science" provides resources about the nature of biological mechanisms that aid the 
discovery of mechanisms. Here, we apply these resources to the discovery of mechanisms 
in medicine. A new diagrammatic representation of a disease mechanism chain indicates 
both what is known and, most significantly, what is not known at a given time, thereby 
guiding the researcher and collaborators in discovery. Mechanisms of genetic diseases 
provide the examples.  
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Introduction 
 While physicists often represent theories as sets of mathematical laws, biologists 
usually represent general knowledge with schematic representations of mechanisms. 
Biologists and medical researchers seek mechanisms because knowing a mechanism 
facilitates explanation, prediction, and control. A theme in work on discovering 
mechanisms is captured by the slogan--the product guides the process. The thesis is that 
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characterizing a mechanism (the product) provides resources to guide the reasoning in its 
discovery (the process) (Craver and Darden 2013).  
 Recent philosophical analysis of mechanisms provides resources to aid the 
discovery of mechanisms. This work is being applied to the discovery of mechanisms in 
medicine. When the goal is to discover a disease mechanism, the nature of the product--
the kind of disease mechanism--guides the process of searching for it. The kinds of 
products to be discussed here are representations of genetic disease mechanisms. In such 
diseases, genetic variants play a major role, together with environmental effects. The 
process is the reasoning to discover such mechanisms. 
 We develop a new graphical interface to aid medical researchers in hypothesizing 
and representing genetic disease mechanisms. We illustrate its use here in detailed 
diagrams of genetic mechanism schemas. The three examples are for a monogenic 
disease chain (cystic fibrosis), a cancer disease chain (affecting DNA mismatch repair), 
and one complex trait disease chain (one chain for one of many mutations for one of the 
loci associated with Crohn's disease).  
  This paper first summarizes recent work in mechanistic philosophy of science 
(e.g., Machamer, Darden, Craver 2000; Bechtel and Abrahamsen 2005; Glennan and 
Illari, forthcoming). As philosophers have shown, diagrams of mechanism schemas play 
important roles in abstractly representing the product to be discovered and guiding the 
process of discovery (e.g., Craver and Darden 2013; Abrahamsen and Bechtel 2015). A 
key idea is to sketch both what is known and what is not known at a given time. Black 
boxes in the sketch indicate where to fill in missing mechanism components. The next 
section of this paper reviews the application of the mechanistic perspective in the 
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philosophy of medicine (e.g., Thagard 1998; 1999; 2003; Darden 2013; Plutynski 2013). 
Then, we show how abstract mechanism chain diagrams serve to represent what is known 
or not known in genetic disease mechanisms. By depicting the state of knowledge about 
the genetic mechanism at a given time, the diagram perspicuously represents gaps in 
knowledge, namely, the sites of ignorance that researchers seek to remove. A set of 
heuristic questions provides guidance in filling the gaps. Three example diagrams of 
disease mechanism chains illustrate our new framework. We contrast our framework with 
two other graphical representation schemes. Finally, we propose future work, including 
plans for a web-based, graphical system that facilitates easy drawing and sharing of the 
individual mechanism chains, as well as discovery of interactions among them. 
Mechanistic Philosophy of Science 
Philosophers have been working for over twenty years to develop what is called the "new 
mechanistic philosophy of science" (Bechtel and Richardson 1993; Glennan 1996; 
Machamer, Darden, Craver 2000). This work calls attention to the importance of the 
search for mechanisms in biology and other disciplines, characterizes the nature of 
mechanisms, and compiles hindsight about the reasoning strategies used in the discovery 
of mechanisms (summarized in Craver and Darden 2013).  
 The discovery of a mechanism typically begins with a puzzling phenomenon. 
When the goal is to find what produces the phenomenon, then one searches for a 
mechanism. That decision rules out other parts of a large search space. One is not seeking 
merely a set of correlated variables. One is not seeking an economical equation that 
describes the phenomenon, although such an equation can provide a constraint in the 
search for a mechanism (Craver 2008; Bechtel and Abrahamsen 2013). One is not 
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seeking a law from which a description of the phenomenon can be derived. One is not 
merely seeking a relation between one cause and the phenomenon as the effect, although 
such a relation provides clues about mechanism components (Darden 2013). Nor is one 
merely seeking to find a pathway, characterized by nodes and unlabeled links which do 
not depict the activities that drive the mechanism. Rather, one is attempting to construct a 
mechanism schema that describes how entities and activities are spatially and temporally 
organized together to produce the phenomenon. 
 Employing a specific characterization of a mechanism provides guidance in 
discovery. One oft-cited mechanism characterization is this: "Mechanisms are entities 
and activities organized such that they are productive of regular changes from start or set 
up to finish or termination conditions" (Machamer, Darden, Craver 2000, p. 3). The goal 
in mechanism discovery is to find the entities and activities, to describe how they are 
organized, and to show how that productively continuous organization produces the 
phenomenon of interest. This characterization directs one to ask: What are the set up and 
finish conditions? Is there a specific, triggering start condition? What is spatially next to 
what? What is the temporal order of the steps? What are the entities in the mechanism? 
What are their structures? What are the activities that drive the mechanism? What are 
their range and their rate? How does each step of the mechanism give rise to the next? 
What are the activity enabling properties that make possible the next step? What are the 
activity signatures (properties of an entity or group of entities in a subsequent step) that 
show the kinds of activities that operated in the previous step to produce them? How was 
each step driven by the previous one? What is the overall organization of the mechanism: 
does it proceed linearly or is the mechanism perhaps cyclic (with no clear start and stop), 
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or is it organized with feedback loops, or does it have some other overall organizational 
motif? Where is it spatially located? In what context does the mechanism operate and 
how is it integrated with other mechanisms? These kinds of questions show how the 
nature of the product provides desiderata that guide the process of its discovery.  
 Mechanism schemas are representations of mechanisms. A "schema" (sometimes 
called a "model" of a mechanism) abstractly represents the structure of a target 
mechanism. Here is an example of a very abstract schema for the mechanism of protein 
synthesis: DNAàRNAàprotein. Such schemas are often depicted in diagrams. William 
Bechtel and his collaborators (Sheredos et al. 2013; Abrahamsen and Bechtel 2015; 
Abrahamsen et al. forthcoming) discuss the many "visual heuristics" that diagrammatic 
representations of mechanism enable. They envisage biologists as reverse engineers, 
trying out various designs to spatially represent the interacting components of the 
mechanisms being discovered. The diagrams make salient specific aspects of the 
organization and operation of the mechanisms.  
 Schemas vary from one another along several dimensions: sketchy to sufficiently 
complete, abstract to specific, small to general scope of applicability, and possible to 
actual (Craver and Darden 2013, Ch. 3). A goal in discovering a mechanism is to convert 
an incomplete sketchy representation into an adequate one for the purpose at hand. 
Incomplete sketches indicate where black (unknown components) and grey (only 
functionally specified) boxes need to be filled in order to have a productively continuous 
schema in which it is clear how each step gives rise to the next. During the construction 
phase of discovery, moving from a sketch to a sufficiently complete schema allows one 
to work in a piecemeal fashion; one can work on one part of the mechanism at a time 
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while leaving other parts as black or grey boxes. Because one is attempting to reveal the 
productive continuity of a mechanism from beginning to end, what one learns about one 
step of the mechanism places constraints on what likely has come before or what likely 
comes after a given step.  
Abstraction comes in degrees and involves dropping details; specification 
involves adding details all the way to instantiation, with sufficient details to represent a 
productively continuous mechanism from beginning to end. A goal in discovery is to find 
a schema at a given degree of abstraction, from a very abstract type of schema with few 
specified components to a fully instantiated one for a particular case. For example, the 
schema DNAàRNAàprotein is very abstract. Steps are condensed in this spare 
representation. However, any given step could be instantiated with specific details if 
needed for the project at hand. A more detailed schema would begin with a particular 
coding DNA sequence, show the transcription to complementary messenger RNA, and 
proceed through the well-known steps of reading the genetic code to order the amino 
acids in a particular protein. 
The desired degree of abstraction depends on the purpose for which the 
mechanism is sought. Although degree of abstraction is an independent dimension from 
the scope of the domain to which the schema applies, more abstract schemas (if they have 
any instances at all) may have a wider scope of applicability. Hence, when the goal of the 
discovery process is to find a very generally applicable mechanism schema, it is likely to 
be represented at a high degree of abstraction, as in the above schema for protein 
synthesis.  
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The move from how possibly to how plausibly to how actually is driven by 
applying strategies for evaluation, such as experimental testing, and strategies for 
anomaly resolution, such as localizing faults and revising the schema. Ideally one wishes 
to find empirical evidence for each step in the mechanism (Craver and Darden 2013, Chs. 
6-9). 
Consider the example of mechanisms connecting a gene mutation to a disease 
phenotype. One starts with the beginning point, e.g., a particular gene mutation, and a 
characterization of the disease phenotype (e.g., a set of symptoms). At the outset, 
between the gene/gene mutation and the phenotypic character is a black box. Having 
evidence of an association between a beginning point (the gene mutation) and the end 
point (the disease phenotype), the discovery task is to fill in the black box to some degree 
of detail. For example, if the goal is to replace an identified mutant gene during gene 
therapy, then it may be unnecessary to find all the intervening steps in the mechanism. A 
highly abstract schema may be sufficient to guide the work to find and replace the faulty 
gene. However, if the goal is to design a therapy to alter an entity or activity in a 
downstream mechanism site, then specific details become important: e.g., one may need 
to find the three-dimensional structure of a protein and identify its active site or locate the 
effect of an environmental factor.  
A given gene to phenotype mechanism has entities of different size levels, 
beginning with the macromolecular DNA, proceeding through protein synthesis, which 
employs ribosomes (particles in the cytoplasm, composed of both proteins and ribosomal 
RNAs), and on to, in some cases, ever larger level cell organelle, membrane, cell, tissue 
and organ components. The appropriate size level depends on what the working entities 
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are in the steps of the mechanism, on how the phenotype is characterized, and how much 
detail is needed for a given project. Hence, a single gene to phenotype mechanism likely 
has entities at many different size levels. (For more on the difference between size levels 
and mechanism levels, see Craver 2007, Ch. 5; Craver and Darden 2013, pp. 21-22) 
 The mechanism discovery process has at least four aspects: characterizing and 
recharacterizing the phenomenon, constructing a schema, evaluating the schema, and 
revising the schema (Darden 2006, Ch. 12; Craver and Darden 2013, Chs. 4-9). These are 
often pursued in parallel and in interaction with one another. Strategies for mechanism 
schema construction are the most relevant here. One localizes where the mechanism 
operates. For gene to phenotype mechanisms, the mechanism starts with a DNA 
sequence; what the final stage is depends on the characterization of the phenotype. Thus, 
the overall structure of the mechanism to be discovered begins with DNA and ends with a 
phenotype. If a library of types of mechanism components is available, then those types 
of components become candidates to be specialized to construct steps of the target 
schema. For example, the module of protein synthesis is a likely module to use in an 
early step in a gene to phenotype mechanism. The strategy of forward/backward chaining 
allows the mechanism chain builder to reason forward from one step to the following step 
or backward to a likely previous step. Activity enabling properties in the previous step 
indicate possible types of mechanism modules to come. Activity signatures indicate what 
possibly came before, because once a specific kind of activity has operated to change the 
state of the next step it leaves specific traces (signatures). For example, a polarly charged 
DNA base is available to bond to its complementary base in the next step of the 
mechanism of DNA replication. Because hydrogen bonding leaves weakly bonded 
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molecular components, when such a signature is detected, one can conclude that polar 
bonding occurred in a previous step (Darden 2002; Darden and Craver 2002; Craver and 
Darden 2013, Ch. 5).  
 With this synopsis of some key features of previous work on mechanisms in hand, 
we now turn to discovery of disease mechanisms. Here too, we argue, the nature of the 
product guides the reasoning process to find it. The product is a schema representing the 
steps in a target disease mechanism. The process is the reasoning by a chain builder to 
construct a diagram to represent the steps, and, while doing so, to fill black boxes to 
remove uncertainties.  
Disease Mechanisms 
In medicine, the following general types of mechanisms are of interest:  
(i) The "normal" biological mechanism (noting that what is "normal" can nonetheless 
vary from person to person) 
(ii) The general disease mechanism, which aids in finding sites for therapy and designing 
therapeutic treatments 
(iii) The specific disease mechanism in an individual patient, which may aid choosing an 
effective therapy 
(iv) The general mechanism of action of a drug or other therapeutic agent 
(v) The specific mechanism of action of drug or therapy in an individual patient, given 
their genetic makeup and personal history 
(vi) Possible mechanisms to account for side effects of therapies on other bodily 
mechanisms 
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 Philosophers of medicine are participating in a lively debate about the role that 
knowledge of the mechanisms of the action of therapies (iii-vi above) should play in 
evidence based medicine. The debated issue is this: is evidence of the effectiveness of a 
therapy from randomized clinical trials sufficient to show the efficacy of a therapy, or is 
knowledge of its mechanism of action needed? (See, e.g., Russo and Williamson 2007; 
Howick 2011; Andersen 2012.) That is not our topic here. Those concerned with 
evidence for a therapy acknowledge that knowing the disease mechanism(s) (type ii and 
iii) can aid the rational design of therapies. That is one of our topics here.  
 The philosopher of science Paul Thagard analyzed reasoning in discovering 
disease mechanisms and possible therapeutic sites. Diseases are of different types, which 
he classified according to their causes (Thagard 1999). Thagard noted that one searches 
for different types of mechanisms if the disease is due to different types of causes. 
Thagard proposed different types of abstract mechanism schemas, based on the different 
types of diseases, including infectious disease, nutritional disease, and molecular genetic 
disease. The causes of diseases, he claimed, are most often identified by statistical and 
experimental means before researchers find the mechanism in which that cause 
participates. However, finding the cause and thereby classifying the kind of disease aids 
the search for the mechanism. In each type, finding where a normal mechanism is broken 
indicates sites for possible therapeutic intervention (Thagard 1998; 2003).  
 As to discovering such disease mechanisms, Thagard queried whether Darden's 
(2002) reasoning strategies for discovering mechanisms might be useful in medicine. 
This paper shows that they are: schema instantiation, modular subassembly, and 
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forward/backward chaining are indeed relevant in disease mechanism discovery, as we 
will see below.  
 Several philosophers and historians of medicine have discussed cystic fibrosis. 
Cystic fibrosis (CF) is a monogenic, autosomal (i.e., not sex-linked), recessive (i.e., a 
patient must have two mutations, one inherited from each parent) disease. The gene 
(labeled CFTR) is large: about 180,000 bases on the long arm of chromosome 7. The 
CFTR protein transports chloride ions across membranes in epithelial cells. Normal 
functioning aids in maintaining appropriate salt balance in those cells. Many different 
types of mutations in this single gene produce variants of the disease. Researchers have 
identified as many as 1324 different disease causing mutations in the CFTR gene 
(http://www.hgmd.cf.ac.uk/ ). These mutations produce a cluster of symptoms affecting 
the lungs, pancreas, liver, and other organs. Lung inflammation and frequent lung 
infections due to the build up of mucus in the lungs are the most serious problems for CF 
patients.  
 The mechanistic analysis applies well to this case. Since the discovery of the 
relevant gene in 1989, medical researchers have extensively studied the beginning steps 
in the disease mechanism and have targeted them for therapy (Darden 2013; Craver and 
Darden 2013, Ch. 11). Sadly, gene therapy has yet to work successfully to put a 
functioning copy of the large CFTR gene into the genome of cystic fibrosis patients 
(Lindee and Mueller 2011). Downstream stages of the mechanism have proved more 
promising targets, especially in mechanisms where the mutation produces a malformed 
protein whose function can be partially corrected with "chaperonin" molecules (Solomon 
2015). Despite extensive study, black boxes remain in the later stages of the mechanism. 
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Still unknown are all the details of exactly how defects in the chloride ion transport 
mechanism produces the final phenotypic symptoms of the disease in the lungs (Darden 
2013). Also puzzling is why patients with the same genetic mutations nonetheless vary in 
the severity of their symptoms (Solomon 2015).  
 Cancer is another disease whose mechanisms have been discussed by 
philosophers. Thagard (2003) classifies cancer as a "disease of cells" due to genetic 
mutations. Hereditary and somatic mutations occur in oncogenes (genes that regulate cell 
division or survival) and tumor suppressor genes (suppress cell division). In contrast, the 
philosopher Anya Plutynski criticizes the view of cancer as merely a genetic disease 
(Plutynski, forthcoming). Cancer, she says, is a "complex process, due to many causes," 
not just to gene, chromosomal, and epigenetic changes but also "causes acting at the level 
of the cell and above" (Plutynski 2013, p. 466). Genetic mutations are often important 
difference makers in cancer etiology, but they are not the only ones. Genetic models, she 
argues, inappropriately "black box" environmental factors (Plutynski 2013, p. 474). 
Mechanism sketches for cancer should depict factors other than genes and indicate where 
such environmental factors should fill in black boxes. 
 The product and the discovery process for complex trait diseases, e.g., Crohn's 
disease, are much more complex than for monogenic diseases and more unknown than 
for the causes of cancer. The causes of this inflammatory bowel disease are hypothesized 
to include not only many genetic variants, but also interactions with the intestinal 
microbiome (the microbes in the gut), and tuning of the immune system through past 
exposures to invading microbes. So far, Crohn's is statistically associated with over 160 
loci in the genome (de Lange et al. 2017). The gene products engage in complex 
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interactions in producing the disease. Hence, Crohn's researchers need to find many 
mechanisms connecting gene variants to aspects of the disease phenotype. These will 
include roles of environmental factors, e.g., diet, and interactions with the gut 
microbiome. Then researchers need to find complex interactions among the products of 
the many mechanisms involved in order to explain the disease and find sites for therapies. 
This paper extends the mechanistic analysis beyond monogenic cases and cancer 
discussed in previous philosophical work to include these complex trait diseases.  
 Genome-Wide Association Studies (GWAS) provide data statistically associating 
genetic variants with disease risk (https://www.ebi.ac.uk/gwas/home). The presence of 
this association implies that either this variant SNP (single nucleotide polymorphism, a 
single base change in the DNA) or another variant nearby is involved in a disease 
mechanism. Many variants are just what may be called "proxy SNPs"; these are single 
base changes in the DNA that are somehow linked to parts of the genome associated with 
the disease, but do not themselves play roles in a disease mechanism. The question arises 
for each identified variant: Is there a disease mechanism that begins with the genetic 
variant and proceeds to the phenotype, characterized as disease risk?  
 Discovery of genetic disease mechanisms, we propose, is aided by an abstract 
diagrammatic representation for disease mechanisms. An abstract diagram sketches the 
overall structure of the product--the disease mechanism--and thereby aids the chain 
builder in the process--reasoning to its discovery.  
Diagrammatic Representations for Genetic Disease Mechanisms  
One analysis of understanding is that it involves the ability to manipulate a mental 
representation (Wilkenfeld 2013). An abstract diagrammatic representation facilitates the 
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formation of an individual's understanding, guides the person in filling it in, and serves to 
convert a single person's visual mental representation into a publically accessible form. 
The proposed abstract general form for mechanism disease diagrams to be discussed 
below plays this role. It has several advantages as a representation of the product to guide 
the process of its discovery: 
 (a) It provides a general framework for integrating and expanding knowledge about 
disease mechanisms.   
(b) It clearly delineates what is known and not known about the mechanism(s) of each 
disease. 
(c) It provides a potential way of finding interactions when multiple mechanisms interact 
to produce or modulate the severity of a disease.  
(d) It allows representation of interacting subsets of mechanisms (found in (c)) in 
individual patients.  
(e) It facilitates identification of sites of potential therapeutic intervention.  
Consider these abstract idealized mechanism diagrams of genetic variant to disease 
phenotype via disease mechanisms:  
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____________________________________________________________________ 
 
Figure 1, The entire mechanism between a genetic variant and disease risk is a black box. 
The question mark queries whether a mechanism actually exists between the two. 
_______________________________________________________________________ 
Figure 1 is a beginning point after a genetic variant is related to disease risk: does that 
variant mark the beginning of a mechanism? In contrast, if indeed a target mechanism is 
found, then an idealized general abstract diagram for it will have components such as in 
Figure 2.  
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_____________________________________________________________ 
 
Figure 2, Abstract genetic disease mechanism chain with no black boxes.  
_________________________________________________________________ 
 Figure 2 shows an idealized diagram of a genetic disease mechanism chain for a 
case where all the components of the chain are understood. It has no black boxes. The 
goal of chain building is to proceed from a figure such as Figure 1, to progressively fill 
the black box, to draw a diagram such as Figure 2 (or else conclude no mechanism likely 
exists). Figure 2 begins with a variant that affects the function of a gene. Rectangles 
represent altered substates, with in box text indicating how the substate is altered. Ovals, 
depicting mechanism modules of groups of activities and entities, label the arrows; text 
inside the oval names the module. The entities and activities of modules transform one 
substate to another. The chain proceeds through successive altered substates to a disease 
phenotype. Blue octagons indicate such potential sites for therapeutic intervention. A 
white cloud entering the chain from below shows a possible role for environmental 
factors. All the boxes are glass boxes; one can look inside and see whatever details are 
relevant. Details in a box or oval may be telescoped (collapsed, as in a folded telescope) 
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when the details are irrelevant. All the lines are green, indicating the chain builder's 
highest confidence level, based on evidence for those steps.  
 Our diagrammatic framework enables us to suggest a set of heuristic questions. 
These serve to guide the chain builder in filling black boxes to remove ignorance and to 
reach a diagram that is complete enough for whatever is the purpose of the work. 
 
Mechanism at all? The first step in removing ignorance is to inquire whether a 
mechanism exists at all. In Figure 1, the chain begins with a genetic variant connected via 
a black box with a question mark to the disease phenotype. For a statistical association, 
the question mark asks whether there is a mechanism at all. To answer that question: try 
to fill the black box with a plausible mechanism. Given failure to find a possible 
mechanism, the chain builder will have to make a judgment call as to when to stop trying. 
Where a specific mutated gene is known, such as in monogenic diseases and some 
cancers, then the first box names the gene and its mutation. The chain builder can draw a 
green arrow to a black box with no question mark to indicate where additional specific 
mechanism components are expected and should be sought.  
 
What kind of genetic variant begins the chain? Once the task becomes to fill the black 
box with a mechanism, the next question is what kind of variant begins the chain? 
Different kinds of variants likely require chains with different kinds of beginning steps. 
For example, a missense variant (a change in one DNA base that results in a changed 
amino acid in a protein) will proceed via protein synthesis. In contrast, a variant in a non-
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coding region of DNA that affects the binding of a regulatory protein will have earlier 
steps before the module of protein synthesis plays a role.  
 
In addition to building the chain forward from the genetic variant, is it possible to 
begin at the end and build the chain backward? Black boxes show missing steps in 
need of elaboration. Because what comes before and what comes after are indicated in 
the diagram, the chain builder can reason forward from the previous step or backward 
from the subsequent one to conjecture what fills the box. Are there activity enabling 
properties in a step that indicate a likely module and a likely substate perturbation in the 
next step? Conversely, are there activity signatures (properties of an altered substate) that 
indicate what kind of activities operated in the previous module, earlier in the chain, that 
produced it?  
 
Do environmental factors play a role? Is there a place where a white cloud representing 
an environmental factor should be added? What kind of substate change follows from its 
insertion?  
 
Does the chain branch into subchains? Does the chain branch at a given step? If so, are 
the subchains mutually exclusive alternatives ("or" at the branch) or do both occur ("and" 
at a branch)? Is there uncertainty on the part of the chain builder such that branches 
should be labeled with "and/or"? 
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Other than branches in the chain, are there other nonlinear organizational motifs 
that need to be added? If no feedback or feed-forward loops are included, the question 
arises as to whether any should be? Are there other nonlinear organizational motifs to 
consider?  
 
Is there a potential site for therapeutic intervention? Can types of therapies for types 
of steps be suggested, e.g., does a misfolded protein indicate that a chaperonin should be 
considered?  
 
How strong is the evidence for each step? How confident is the chain builder in each 
step? As noted above, a black box with a question mark asks whether there is anything to 
be discovered at that point, either whether a mechanism as a whole exists or whether a 
branch of a chain exists. A black box without a question mark indicates a likely but 
currently unknown substate, mechanism module, or group of substates and mechanism 
modules. Green, pink and red colors of the lines indicate the confidence level of the chain 
builder in each specific perturbed substate and arrow/module. Just like black boxes, red 
and pink colors indicate where more work is needed to increase confidence, to convert 
red and pink to green. Evidence for particular steps includes the following: standard 
biological knowledge, one or more reliable published sources provide evidence for the 
step, and experimental evidence. (The diagrams below illustrate the use of all three kinds 
of evidence.) 
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These questions aid the chain builder in using the diagram to depict kinds of ignorance 
and direct resources to remove it.  
 
Web-based Graphical Interface for Chain Building 
We are developing a web-based graphical interface to aid medical researchers in 
hypothesizing and representing genetic disease mechanisms. The interface is 
implemented using the conventions discussed above. We have used it to produce more 
detailed diagrams, such as those below. These three figures provide examples for a 
monogenic disease chain, a cancer disease chain, and one (of what will be many) 
complex trait disease chain.  
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_______________________________________________________________________ 
 
Figure 3, A disease mechanism chain for cystic fibrosis, an example of a monogenic 
disease. 
______________________________________________________________________ 
 Figure 3 shows a mechanism disease chain for cystic fibrosis (CF). It begins with 
the mutation, DeltaF508, in the cystic fibrosis transmembrane conductance regulator 
(CFTR) gene. This is the most common mutation among CF patients in the United States. 
Normally the CFTR protein inserts into epithelial cell membranes and transports chloride 
ions across the membrane. In this mutant form, three DNA bases are missing, resulting in 
one missing amino acid in the protein. The protein misfolds. The first branch in the chain 
indicates that some misfolded proteins are degraded but others are released from the 
endoplasmic reticulum (ER), where it is synthesized. This lower abundance of the protein 
and its misfolding results in altered concentrations of the misfolded protein in epithelial 
cells in the pancreas, sweat glands, and lungs, shown in the next three branches. This is a 
well-studied case so all the lines in the beginning of the mechanism chain are green. The 
black boxes and red arrows (toward the end in the lower branch of the chain) indicate the 
controversy that still surrounds exactly what contributes to the build up of thick mucus in 
the lungs. One hypothesis is that improper salt balance produces the mucus build up 
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(shown in the top chain coming out of the lungs rectangle). Another hypothesis is that a 
contributing factor is the break down of the overexpressed immune cells, neutrophils, that 
are recruited to fight invading bacteria (shown in the loop in the bottom branch of the 
chain). (For more details, see Darden 2013.) 
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_______________________________________________________ 
 
Figure 4, Mechanism chain diagram for a cancer gene variant in the human gene MSH2. 
_____________________________________________________________  
 Figure 4 is an example of a disease mechanism chain for cancer. This is a 
hypothesized mechanism chain for a germline DNA variant in the human gene MSH2. 
The ID number identifies the particular variant. The DNA base change is expected to lead 
to nonsense mediated decay (NMD), decreasing the messenger RNA abundance by half, 
and as a consequence, also decreasing MSH2 protein abundance. As a result, all the 
complexes of this protein with other proteins will also be of reduced abundance, hence 
the "and" at the first branch. The Le Chatelier's Principle refers to a state in which, e.g., 
the concentration of a reactant changes in a system in equilibrium such that the 
equilibrium will shift so as to tend to counteract the effect. This activity lowers the 
abundance of macromolecular complexes in the next steps in all three branches. Then, the 
branches show the effects of less DNA mismatch repair of both short and longer 
mismatch regions in the DNA, as well as less apoptosis (programed cell death) triggered 
by recognition of drug induced DNA damage. Results include greater accumulation of 
somatic mutations, hence increased cancer risk. Greater microsatellite instability occurs, 
which may also somehow increase cancer risk, indicated by the black box with a question 
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mark.  The top branch of the chain shows the path to drug resistance. (For details, see the 
review, Li 2008.) 
 
_____________________________________________________________ 
 
Figure 5 shows a chain for one variant in the MST1 gene associated with increased risk of 
Crohn's disease  
______________________________________________________________ 
Figure 5 is an example of one of the hypothesized mechanism chains for Crohn’s disease, 
originating in a locus containing a GWAS marker at the MST1 gene, which codes for 
MSP (Macrophage Stimulating Protein). The mechanism begins at the perturbed DNA 
substate on the left, and progresses through protein, protein-protein complex, cell 
signaling, innate immune response, and gut barrier layer stages to disease risk. In this 
view, some parts of the chain, at the DNA, protein, and protein complex stages, are fully 
expanded, while others are partly telescoped (for example "cell signaling" and "innate 
immunity"). These telescoped steps have multiple substate perturbations and mechanism 
modules within them. (For details on research on this chain, see Gorlatova et al. 2011.) 
Black boxes, as well as pink and red lines, indicate uncertainty. The "or" at the first 
branch indicates two different ways that the chain might branch. The next "and/or" 
indicates that one or both of the branches may occur; the chain builder is not yet certain 
which is the case. This MST1 chain represents just one of the many mechanisms involved 
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in Crohn's disease. Much work remains to find additional chains and the ways they 
interact with each other.  
 This diagrammatic method clearly illustrates the way an abstract representation of 
the product to be discovered guides reasoning to its discovery through various stages. 
Admittedly, this diagrammatic representation abstracts away from many features of 
mechanisms discussed above. It is an open question whether any features of more fully 
represented mechanisms will need to be added. Note that the diagrams do not include 
structures of the proteins and protein complexes, although, if needed, it would be easy to 
add a link to the protein structure database. Also omitted are quantitative rates by which 
activities operate or quantitative measures of abundance of entities; this is a qualitative 
representation. Furthermore, the locations of the mechanism steps are not graphically 
shown, e.g., whether the steps occur in the nucleus, in the cytoplasm, within cell 
organelles, or elsewhere; however, when relevant, text in the altered substate box does 
indicate location, such as epithelial cells. It is an open question whether such general 
features of mechanisms (structures, rates, spatial locations) will need to be represented to 
fulfill the goals of adequately explaining the disease and locating sites for therapy. 
Should the need arise, the general philosophical analysis of mechanisms provides a 
storehouse of items that can be added to the simplified graphic in the future. 
 Our work contrasts with other graphical forms of representations; we discuss two 
here. One type is a directed acyclic graph (DAG) to represent causal chains. Philosophers 
of science are engaged in a lively debate about the adequacy or inadequacy of DAGs for 
representing normal biological mechanisms (e.g., Gebharter and Kaiser 2014; Kaiser 
2016; Weber 2016). From our perspective, causal graphs are impoverished in merely 
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having unlabeled edges that represent generic cause relations. In contrast, our mechanism 
diagrams indicate the specific kind of activity or the group of entities and activities in a 
mechanism module that effect each particular instance of casual production.  
 Biologists have developed other graphical frameworks, but not (so far as we 
know) ones using analyses from the new mechanistic philosophy of science to 
specifically represent genetic disease mechanisms. Most represent normal molecular 
biological pathways. (For a list see, e.g., Jin et al. 2014.) One of the best developed the 
Kyoto Encyclopedia of Genes and Genomes. The KEGG Pathway database is a 
collection of manually drawn graphical diagrams. These represent molecular pathways 
for metabolism, genetic information processing, environmental information processing, 
other cellular processes, some human diseases, and drug resistance (Kanehisa 2017). The 
disease diagrams are represented by perturbations in normal pathways.  
 The KEGG disease diagrams differ from our framework in numerous ways. 
Unlike our diagrams, KEGG depicts diseases in pathway wiring diagrams of groups of 
normal pathways with genes associated with a disease in color-coded rectangles. 
Furthermore, the focus is only on the early stages involving genes, proteins, and 
molecular interactions. In contrast, each of our diagrams begins with a specific single 
gene mutation and traces the changes resulting from that mutation through numerous 
other stages to the disease phenotype. 
 For example, in KEGG the Crohn's disease pathway is part of the pathway for 
inflammatory bowel diseases (IBD) in general. The IBD pathway depicts numerous genes 
and proteins (in rectangular boxes) in their normal pathways. A few genes known to be 
associated with diseases (not just Crohn's) are colored pink in contrast to normals, which 
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are green.  Light blue boxes indicate actual drug targets. Some anatomical details are 
depicted, such as a breach in the gut wall and a macrophage (an immune cell). Types of 
lines connecting genes and gene products indicate types of interactions, such as 
inhibition, activation, indirect effect, or dissociation. In contrast, our diagrams have ovals 
with text to label the arrows, thus showing the activities or mechanism modules that 
produce perturbed substates. Any new kind of activity easily fits within our framework 
whereas KEGG will need a new graphical symbol. Consequently, our framework is more 
easily extendable.  
 Also unlike ours, the KEGG pathway diagrams do not indicate confidence levels 
nor do they include black boxes to show ignorance. Our diagrams are thus better for 
directing the discovery process to produce the product of a genetic disease mechanism by 
filling black boxes, resolving uncertainties about branches, and increasing confidence 
levels.  
Conclusion 
 This paper argues for the thesis that the product shapes the process: knowing what 
is to be discovered provides guidance as to how to discover it. Here the product is a 
schema to represent steps in a disease mechanism from gene variant to disease phenotype. 
Heuristic questions and abstract diagrams aid the reasoning process to discover a specific 
disease mechanism chain. By indicating black boxes and uncertainties, the chain builders 
represent their ignorance at a given time and show where to focus additional work. This 
new diagrammatic representational tool, grounded in philosophical analysis, aids in 
storing collective knowledge and guiding collective discovery.  
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 Plans for future work include finding standardized ontology terms (Arp et al. 
2015) for each stage of genetic disease mechanisms (e.g., Gene Ontology 2015). Such 
standardized terminology is especially important to facilitate finding interactions among 
the related chains. This standardization will also foster communication between groups of 
experts to complete the parts of the chains in their areas of expertise. An even longer-
range goal is to apply this work in precision medicine. That goal requires finding specific 
interacting chains for individual patients (or groups of patients), given variability in their 
genes, environment, and lifestyle, so that personalized therapy can be designed and 
administered.  
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